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GREENAMYRE, J. T. AND A. B. YOUNG. Excitatory amino acids and Alzheimer's disease. NEUROBIOL AGING 10(5) 593-602, 
1989.--Excitatory amino acids (EAA) such as glutamate and aspartate are major transmitters of the cerebral cortex and hippocampus 
and EAA mechanisms appear to play a role in learning and memory. Anatomical and biochemical evidence suggests that there is both 
pre- and postsynaptic disruption of EAA pathways in Alzheimer's disease. Dysfunction of EAA pathways could play a role in the 
clinical manifestations of Alzheimer's disease, such as memory loss and signs of cortical disconnection. Furthermore, EAA might be 
involved in the pathogenesis of Alzheimer's disease, by virtue of their neurotoxic (excitotoxic) properties. Circumstantial evidence 
raises the possibility that the EAA system may partially determine the distribution of pathology in Alzheimer's disease and may be 
important in producing the neurofibrillary tangles, RNA reductions and dendritic changes which characterize this devastating disorder. 
In this article, we will review the evidence suggesting a role for EAA in the clinical manifestations and pathogenesis of Alzheimer's 
disease. 
Alzheimer's disease Excitatory amino acids Excitotoxin Glutamate Kainate NMDA Quisqualate 
Receptor 
ALZHEIMER'S disease is the most common dementing illness in 
the Western world; it affects about one in six persons over the age 
of 65 (60). Alzheimer's disease has traditionally been viewed as a 
"cort ical"  dementia (143). It is marked by memory loss, person- 
ality changes and signs of cortical disconnection such as apraxia, 
aphasia and agnosia. In keeping with this clinical impression of 
cortical dysfunction, substantial pathology in Alzheimer's disease 
falls on the cortical structures (89). The hallmarks of Alzheimer's 
disease are neurofibrillary tangles and amyloid-containing neuritic 
plaques in cerebral cortex and hippocampus (60). In addition, the 
large pyramidal neurons in the neocortex and in the CA1 region of 
hippocampus are significantly depleted (71,137). 
More recently, substantial subcortical pathology has been 
noted. In the nucleus basalis of Meynert and other areas of the 
basal forebrain, a considerable loss of cholinergic neurons is 
usually observed (106). Similarly, serotonergic neurons in the 
median raphe (70) and noradrenergic neurons in the locus ceruleus 
(11) are variably depleted, especially in early onset cases. Empha- 
sis has been placed upon the loss of cholinergic innervation to the 
cerebral cortex and it has been suggested that the dementia of 
Alzheimer's disease is primarily due to this deficit (26). However, 
several lines of evidence argue against this notion. First, a subset 
of demented Alzheimer's patients with typical neuropathological 
findings have normal levels of choline acetyl transferase (CAT) in 
the cerebral cortex (96). Second, some demented Alzheimer's 
patients have normal numbers of cholinergic neurons in the 
nucleus basalis of Meynert (101,103). Finally, in another neuro- 
degenerative disorder, olivopontocerebellar atrophy, basal fore- 
brain neurons are lost and there is a concomitant reduction of 
cortical CAT activity of the same magnitude as that seen in 
moderate to severe, clinically disabling Alzheimer's disease t61). 
However, these patients are not demented, "and scored within or 
close to the normal range on a simple mental status screening 
examination." It should be noted that detailed neuropsychological 
testing revealed "generally mild" deficits in these patients. The 
authors concluded that "cholinergic reduction may explain only 
part of the pathophysiology of the dementia of [Alzheimer's 
disease]." Thus it is unclear whether pathology in one neurotrans- 
mitter system is primarily responsible for the clinical signs and 
symptoms of Alzheimer's disease. Also a matter of controversy is 
whether the primary lesion in Alzheimer's disease is cortical or 
subcortical (3). 
Examination of the major cortical and hippocampal neurotrans- 
mitter systems is of importance because of the profound cortical 
and hippocampal pathology in Alzheimer's disease. Excitatory 
amino acids, such as glutamate and aspartate, are thought to be the 
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principal excitatory neurotransmitters of cortical and hippocampal 
neurons (36, 39, 44). In this article, we will review the evidence 
that excitatory amino acids are affected in Alzheimer's disease, 
that they may play a role in the pathogenesis of Alzheimer's 
disease and that dysfunction of the excitatory amino acid system 
may be responsible for some of the clinical manifestations of this 
disease. 
EXCITATORY AMINO ACIDS AS NEUROTRANSMITTERS 
Glutamate, aspartate, homocysteic acid and cysteine sulfinic 
acid are all putative endogenous excitatory amino acid neurotrans- 
mitters. Of these, glutamate is the best characterized and is likely 
to serve as the major excitatory neurotransmitter of the central 
nervous system (36, 39, 44). This dicarboxylic, acidic amino acid 
is the most abundant amino acid in the brain (39). Glutamate is 
intimately involved in intermediary metabolism and it can be 
synthesized via a number of different pathways. The rate limiting 
step for the synthesis of the neurotransmitter pool of glutamate, if 
there is one, is unknown (39). Neurotransmitter glutamate is 
apparently actively taken up and stored in synaptic vesicles (88) 
and, upon depolarization, glutamate is released in a calcium- 
dependent fashion (105). Glutamate released into the synaptic cleft 
is rapidly inactivated by a sodium-dependent high-affinity uptake 
system which is present in both neurons and glia (39). 
Under appropriate experimental conditions, the molecular pro- 
cesses mediating calcium-dependent release and high-affinity 
uptake can be measured to map putative EAA pathways. Most 
homogenate and tissue slice autoradiographic methods appear to 
measure selectively the presynaptic neuronal uptake site (39). 
Because these processes are localized to nerve terminals, EAA 
uptake or release will be reduced in the terminal fields (projection 
sites) of lesioned EAA pathways. More recently, immunocy- 
tochemicat methods have been employed to directly visualize 
conjugated glutamate in neurons and glia (134). This technique 
appears to label the neurotransmitter pool of glutamate, although 
this is a subject of controversy (95) and different antibodies may 
yield differing results. By combining lesion studies with measures 
of uptake and release, immunocytochemistry and electrophysiol- 
ogy, a wide variety of putative EAA pathways have been identi- 
fied (38). These include corticocortical pathways, corticofugal 
pathways (including fibers to striatum, thalamus, brainstem and 
spinal cord), hippocampal afferents, intrinsic neurons and effer- 
ents, cerebellar afferent fibers and intrinsic cells, primary sensory 
afferents and spinal cord intrinsic neurons. 
EAA Receptors 
The excitatory actions of EAA are mediated through at least 
four different receptor types (90, 125, 142). Under the most 
common receptor classification scheme, N-methyl-D-aspartate 
(NMDA), quisqualate and kainate receptors have been named for 
the agonist which is most specific at that receptor type. There is 
also a "metabotropic" receptor which is coupled to inositol 
phosphate metabolism (90,125). Virtually all cells in the central 
nervous system are depolarized by EAA, suggesting the presence 
of receptors on most neurons. Some EAA, such as glutamate, are 
"nonselective agonists," meaning that they can interact with each 
of the receptor types. Quisqualate receptors appear to mediate fast 
excitatory neurotransmission (29). Although somewhat controver- 
sial, NMDA receptors also appear to function in normal synaptic 
transmission (22,138). The function of kainate receptors is un- 
clear. 
The NMDA receptor is the best characterized of the three 
receptor types. Glutamate, aspartate, homocysteate and quinoli- 
hate are endogenous EAA that can activate the NMDA receptor. 
whereas NMDA itself is a synthetic analog which specifically 
activates this receptor (41,78). The NMDA recognition site 
(binding site) is coupled to an ion channel, which is gated by 
magnesium in a voltage-dependent manner (79,93). Thus, when 
the cell is in its normal polarized state, the ion channels are 
blocked by magnesium and the NMDA receptor is difficult to 
activate. However, when, for any given reason, the neuron 
becomes relatively depolarized, the magnesium blockade is lifted. 
Dissociative anesthetics, such as phencyclidine (PCP), ketamine 
and the recently developed drug MK-801, bind to and block this 
ion channel, and thereby act as noncompetitive antagonists of the 
NMDA receptor system (59, 67, 138). Anatomical and biochem- 
ical studies indicate that the PCP receptor is associated with the 
NMDA receptor ion channel complex (74) and, currently, the term 
"PCP receptor" is considered synonymous with the NMDA 
receptor ion channel (109). The NMDA receptor complex also has 
a glycine recognition site, activation of which appears to be 
necessary for NMDA receptor function (58,62). Thus, the NMDA 
receptor is a large macromolecular complex with various recog- 
nition and regulatory sites. In contrast to our current understanding 
of the NMDA receptor, the structure and function of quisqualate 
and kainate receptors are just beginning to be elucidated. 
Recently, receptor binding assays have been developed to label 
selectively the NMDA (45, 83, 85), quisqualate (17, 52, 86, 91) 
and kainate receptor (10, 51, 81, 121, 140) recognition sites, as 
well as the PCP receptor (74, 124, 141, 149) and the NMDA 
receptor-associated glycine site (15, 23, 68, 1 t2, 130). Quantita- 
tive receptor autoradiography has been used to determine the 
pharmacological characteristics and precise regional localization 
of these receptor types. The regional distributions of NMDA 
recognition sites, PCP receptors and glycine recognition sites are 
highly correlated (23,74). The density of NMDA receptors is 
higher in the forebrain than in brain stem, cerebellum or spinal 
cord, and is especially high in stratum moleculare of dentate 
gyrus, stratum radiatum of CAI and outer layers of cerebral 
cortex; receptor density is intermediate in the basal ganglia and 
thalamus. Quisqualate receptors are most prevalent in the molec- 
ular layer of cerebellum, outer layers of cerebral cortex, stratum 
moleculare of the dentate gyms, stratum radiatum of the hippo- 
campus and striatum. Moderate numbers of quisqualate receptors 
are found in thalamus and hypothalamus. Kainate receptors are the 
most dense in the stratum lucidum of the hippocampus. Moderate 
levels of kainate receptors are found in the deep layers of cerebral 
cortex, the striatum and granular layer of cerebellum; there is less 
binding in outer layers of cerebral cortex, thalamus and cerebellar 
molecular layer. Thus, EAA receptors are distributed widely 
throughout the brain, especially in cortex and hippocampus. 
EAA in Learning, Memory. and Plasticity 
In addition to their function as excitatory neurotransmitters. 
EAA appear to play important roles in learning and memory, 
developmental synaptic plasticity, neuronal survival and dendritic 
outgrowth and regression. In the hippocampus. NMDA antago- 
nists can block certain aspects of the development of long-term 
potentiation (LTP), a model of memory formation (19. 20. 50). 
These agents also impair spatial discrimination learning in rats 
(87). In some cases, normal synaptic plasticity is dependent upon 
NMDA receptor activation. For example, the plasticity of binoc- 
ular connections in the visual cortex of the kitten can be dis- 
rupted by a one hour exposure to the NMDA antagonist, amino- 
phosphonopentanoic acid (110). Similarly, normal activity-depen- 
dent developmental plasticity of the visual system can be disrupted 
by NMDA antagonists (63). 
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It has also been suggested that activation of the NMDA 
receptor may exert a trophic influence during development. 
During differentiation, activation of the NMDA receptor promoted 
the survival of cultured cerebellar granule cells (6). This effect was 
stage-dependent and blocked by a competitive NMDA antagonist. 
Furthermore, at higher, subtoxic doses, EAA can cause regression 
and simplification of the dendritic arbor of hippocampal pyramidal 
cells in vitro (75,76). EAA, therefore, have biphasic effects, 
promoting growth and differentiation at low concentrations and 
inhibiting them at higher concentrations. 
EAA as Neurotoxins 
A unique property of EAA neurotransmitters is their neurotox- 
icity (94, 114, 115). The ability of EAA to cause neuronal 
depolarization correlates with their ability to produce axon-sparing 
neurotoxic lesions and has led to the concept of "excitotoxins" 
(94). Both the excitatory and toxic effects of EAA can be blocked 
by receptor antagonists, suggesting that both phenomena are 
mediated by receptors. Excitotoxicity can occur by activation of 
NMDA, quisqualate or kainate receptors. The mechanism of 
neurotoxicity appears to involve 2 processes (115). First, depolar- 
ization can result in passive chloride influx, which causes subse- 
quent cation and water entry and may lead to osmotic lysis. 
Second, depolarization through NMDA receptors also causes 
calcium influx (18), which leads to delayed neuronal damage due 
to mitochondrial dysfunction and protease and lipase activation. 
Other factors may also contribute to excitotoxicity. For example, 
under hypoxic/ischemic conditions, high affinity glutamate uptake 
is depressed such that glutamate may exert more prolonged effects 
upon its receptors (120). In addition, when neurons are unable to 
maintain their normal membrane potential, the voltage-dependent 
magnesium gating of the NMDA receptor ion channel is lifted and 
the neurons are more susceptible to NMDA receptor-mediated 
damage (92). Neurotoxicity is therefore enhanced by any process 
that disrupts cellular energy metabolism. 
Because of their ubiquitous distribution and neurotoxic poten- 
tial, it has been proposed that EAA may be involved in the 
pathogenesis of both acute and chronic neurodegenerative diseases 
(36, 44, 94, 115). For example, several lines of evidence suggest 
that excitotoxicity is involved in hypoxic/ischemic brain damage 
(114). Hypoxia/ischemia causes a simultaneous large increase in 
glutamate release (9) and a marked depression of high-affinity 
glutamate uptake (120). Removal of EAA innervation to a given 
region protects against subsequent hypoxic/ischemic damage 
(144). Global hypoxia/ischemia produces preferential damage of 
superficial cortical layers, the CA1 region of hippocampus, 
striatum and cerebellar Purkinje cells, regions with high densities 
of EAA receptors (14, 45, 85). Most importantly, in models of 
global and focal hypoxia/ischemia, EAA antagonists exert a 
profound protective effect (40, 115, 122). Similarly, there is 
evidence suggesting a role for EAA in the pathogenesis in 
Huntington's disease (8, 27, 69, 147), epilepsy (126), hypoglyce- 
mic brain damage (145), lathyrism (132) and amyotrophic lateral 
sclerosis (133). 
EXCITATORY AMINO ACID MARKERS IN ALZHEIMER'S DISEASE 
EAA Levels 
The simplest but least specific marker of EAA function is 
measurement of EAA levels. Glutamate and aspartate are inti- 
mately involved in intermediary metabolism in the central nervous 
system, and the neurotransmitter pool of these amino acids is only 
a small fraction of the total. However, in regions with dense 
glutamatergic innervation, the neurotransmitter pool of glutamate 
and aspartate may be as high as 30%-40% of the total (39). 
Several studies have examined excitatory amino acid concentra- 
tions in Alzheimer's and control brains. Some of these studies 
have shown significant decreases in glutamate levels in cortex and 
hippocampus of Alzheimer's patients (4, 35, 116), but other 
studies have shown no changes (102,104). A somewhat different 
approach was taken by Hyman et al. (53). These workers had 
previously shown that the cells of origin of the perforant pathway 
to the hippocampus are destroyed in Alzheimer's disease (54). 
Because this pathway is believed to be glutamatergic, they 
microdissected a portion of the pathway's terminal zone and found 
an 83% decrease in the level of free glutamate in Alzheimer's 
disease patients (53). More recently, Bowen and colleagues have 
examined amino acid levels in biopsy samples from very early 
Alzheimer's disease and control brains (108). They reported a 
significant decrease in glutamate levels in the temporal cortex and 
a significant increase in aspartic acid in the temporal and frontal 
cortex of Alzheimer's disease patients. In later stages of the 
disease, samples of brain obtained within three hours of death 
were also analyzed for amino acids, and a much larger decrease in 
glutamate was found in the Alzheimer's cases. Amino acids have 
also been examined in the cerebrospinal fluid of Alzheimer's 
disease patients and controls (127). Although there were no overall 
differences in aspartic or glutamic acid in the Alzheimer's disease 
patients, there was a significant correlation between cerebrospinal 
fluid levels of glutamate and cognitive test scores. 
In summary, measurements of excitatory amino acid levels 
have yielded conflicting results. However, when these measure- 
ments were made in regions of dense glutamatergic innervation, in 
biopsy samples or in postmortem samples obtained within three 
hours of death, there did appear to be significant decreases in 
glutamate levels in Alzheimer's patients. 
EAA Uptake and Release 
More specific biochemical markers for EAA neurons include 
sodium-dependent high-affinity uptake and calcium-dependent 
release (39,44). High-affinity sodium-dependent uptake was meas- 
ured in a synaptosomal preparation of previously frozen brains 
from Alzheimer's disease and control subjects (49). Under these 
conditions there was a 60% decrease of uptake sites in cortical and 
hippocampal regions. However, studies in rat brain have indicated 
that freezing results in a 50%-80% decrease in uptake activity 
compared to fresh tissue, and prolonged freezing results in a 
further decrement of uptake (49,117). 
More recently, some laboratories have examined sodium- 
dependent D-aspartate binding because it was thought that this 
would be a more stable marker of the uptake site (24, 28, 123). 
Unfortunately, in homogenates (30) and, more recently, in auto- 
radiographic assays (13,48), sodium-dependent D-aspartate bind- 
ing has been found to have properties inconsistent with neuronal, 
presynaptic uptake sites. In homogenates (30), thorough washing 
of membranes in distilled water abolishes subsequent sodium- 
dependent D-aspartate binding. This, and several other inconsis- 
tencies have led the authors to conclude that D-aspartate binding 
"does not represent binding to the transport cartier." In an 
autoradiographic assay (48), sodium dependent D-aspartate bind- 
ing has a regional distribution unlike that expected for a presyn- 
aptic neuronal uptake site. Furthermore, lesions of EAA pathways 
do not result in decreased binding (uptake) in the terminal fields of 
those pathways, contrary to what would be expected for a marker 
of the neuronal uptake site (13,48). 
In fresh unfrozen tissue, Bowen and colleagues (108) have 
demonstrated a 40%-50% decrease in D-aspartate synaptosomal 
uptake in Alzheimer's disease brain. EAA release from biopsy 
samples of temporal cortex from patients with Alzheimer's disease 
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was reportedly normal (128); however, the calcium dependence of 
release was not examined. More recently, the same authors have 
reported that calcium-dependent release could not be demonstrated 
in fresh tissue obtained from prompt postmortem tissue samples 
(108). 
EAA Immunocytochemistry" 
Another direct measure of EAA neurons is by means of EAA 
immunocytochemistry (134). The interpretation of glutamate and 
aspartate immunocytochemistry is somewhat controversial and 
may depend, in part, on the particular antibody used. It is also 
unclear whether antibodies to these compounds are labeling a 
metabolic or neurotransmitter pool (95). Despite these uncertain- 
ties, it appears that in many regions glutamate and aspartate 
immunocytochemistry label populations of putative EAA neurons. 
This technique has been applied to the study of Alzheimer's 
disease brains and it has been shown by two different laboratories 
that glutamate immunoreactivity is localized in cortical and 
hippocampal pyramidal neurons, many of which contain neu- 
rofibrillary tangles (64,73). In the future, it may be possible to use 
immunocytochemistry to perform quantitative morphometric stud- 
ies of EAA neurons in Alzheimer's disease brains. 
EAA Receptors 
In addition to these presynaptic measures of EAA neurons, 
there is also evidence of postsynaptic EAA dysfunction in Alzhei- 
mer's disease. Greenamyre et al. (47) described a loss of gluta- 
mate binding sites in the neocortex of Alzheimer's patients when 
compared to normal controls and patients with Huntington's 
disease. When subtypes of EAA receptors were examined, it 
appeared that NMDA receptors were affected more than quis- 
qualate receptors. A similar, profound loss of NMDA receptors 
was found in the hippocampus of Alzheimer's disease patients 
(46). Represa et al. (111) also reported large losses of NMDA 
receptors in Alzheimer's hippocampus. In contrast, Geddes et al. 
(43) and Cowburn et al. (24,25) found no significant NMDA 
receptor changes in neocortex or hippocampus. 
Maragos et al. (72) described a loss of PCP receptors (NMDA 
receptor ion channels) in CA1, CA3 and subiculum of the 
hippocampus of Alzheimer's disease patients. A 40% loss of PCP 
receptors in CA1 was reported by Cotman and colleagues (82). 
Interestingly, although Cotman and colleagues reported an average 
40% loss of PCP receptors in CA1 and no significant loss of 
NMDA sites, they found a correlation coefficient of 0.92 between 
the 2 sites in the same brains (82). Simpson et al. (123) examined 
PCP receptor binding in homogenates of Alzheimer's brains and 
they found no significant changes in PCP receptors in hippocam- 
pus, temporal cortex or caudate nucleus, but they did observe a 
35% decrease in frontal cortex. 
Geddes et al. (43) described an expanded distribution of 
kainate binding sites in the molecular layer of the dentate gyrus in 
Alzheimer's disease hippocampi, but the density of binding sites 
was unchanged. In contrast, Represa et al. (111) reported a 
significant loss of kainate sites in dentate gyrus and no expansion 
of the distribution of these sites. 
There may be several reasons for the discrepancies in the 
results of NMDA and PCP receptor binding in Alzheimer's disease 
reported by different laboratories. First, differences in assay 
conditions and buffers may produce different results. Second, 
receptor binding in homogenate preparations may mask significant 
changes in discrete anatomical laminae. Third, severity of disease 
might determine the degree of receptor changes measured. Further 
studies will be necessary to clarify these issues. The studies to 
date, however, suggest that the degree of NMDA and PCP 
receptor loss is related to the severity of Alzheimer's pathology 
(42, 72. 82. 111). However, the loss of the NMDA/PCP receptor 
complex is not a simple reflection of neuronal loss as discussed 
below. Furthermore, given the discrete distribution of NMDA 
receptor losses in hippocampus, it is likely that homogenate 
studies (24, 25, 123) would not detect these changes. 
In summary, measurement of EAA markers including endog- 
enous EAA levels, synaptosomal uptake and immunocytochemis- 
try provides compelling evidence for loss of EAA-utilizing neurons 
in Alzheimer's disease. Because these EAA neurons themselves 
receive extensive EAA input, it would be expected that degener- 
ation of these cells (pyramidal cells of the neocortex and CA I 
region of hippocampus) would result in a loss of EAA receptors. 
In fact, autoradiographic studies have generally shown a loss of 
NMDA receptors in certain hippocampal subfields in Alzheimer's 
disease (46, 72, 82, 111). Of critical importance, but still 
unanswered, is the question of when during the course of the 
disease these changes in EAA transmission occur. The clinical 
implications of this pre- and postsynaptic disruption of EAA 
neurotransmission are discussed in a subsequent section. 
THE RELATIONSHIP OF EAA TO PATHOLOGY IN ALZHEIMER'S 
DISEASE 
Neurofibrillary Tangles 
A characteristic neuropathological finding in Alzheimer's dis- 
ease is the presence of neurofibrillary tangles in the perikarya of 
many neurons in the cortex, hippocampus and basal forebrain 
(60,136). The neurofibrillary tangles are composed of accumula- 
tions of paired helical filaments (136). Interesting observations 
have been reported relating EAA to neurofibrillary tangles. One 
study (which has not been replicated) suggested that incubation of 
cultured human neurons with aspartate or glutamate induced the 
formation of paired helical filaments similar to those which make 
up neurofibrillary tangles (32). Antibodies against the abnormal 
cytoskeletal elements found in Alzheimer's disease have not been 
used to determine whether the epitopes on the paired helical 
filaments seen in this culture experiment are in fact similar to those 
on the paired helical filaments in Alzheimer's disease. On the 
other hand, immunocytochemical data do suggest that the anti- 
genic composition of neurofibrillary tangles observed in the 
amyotrophic lateral sclerosis-parkinsonism-dementia of Guam is 
similar to that of tangles observed in Alzheimer's disease (118). 
This observation suggests that there is a common pathogenetic 
mechanism for neurofibrillary tangle formation in these diseases. 
Because the pathogenesis of amyotrophic lateral sclerosis-parkin- 
sonism-dementia of Guam has been tentatively linked to an 
excitotoxin acting at the NMDA receptor (133), a similar excito- 
toxic mechanism may play a role in the formation of neurofibril- 
lary tangles in Alzheimer's disease. The mechanism by which 
EAA induce paired helical filaments is unknown. One might 
speculate that EAA, by opening calcium channels, or by activation 
of the inositol phospholipid cascade, could activate protein kinases 
and cause abnormal phosphorylation of neurofilament or tau 
proteins. Such a possibility has been proposed as a mechanism for 
neurofibrillary degeneration (57). 
RNA Reductions 
In a study of 17 patients with Alzheimer's disease verified 
histologically, cognitive test scores correlated highly with patho, 
logical changes in large cortical pyramidal (EAA) neurons, as 
assessed by cell loss, reductions in nuclear and nucleolar volumes 
and cytoplasmic RNA content (89). A disorder in RNA synthesis 
has been demonstrated repeatedly in Alzheimer' s disease (12, 65. 
89). In both human and mouse neurons, glutamate, in subtoxic 
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doses can reduce RNA content (32,34). The alteration in RNA 
metabolism may simply indicate that damaged neurons process 
RNA differently. Alternatively, reductions in neuronal nucleolar 
volumes and cytoplasmic RNA content (89) may be markers for 
excitotoxic damage. 
Distribution of Plaques and Tangles 
Careful, systematic examination of the distribution of neu- 
rofibrillary tangles and senile (neuritic) plaques suggests that these 
lesions do not occur randomly, but may have an anatomical basis. 
Regions of cortex that are interconnected by cortical association 
pathways are much more severely affected than are primary motor, 
somatosensory, visual or auditory cortex (37,99). The laminar 
distribution of plaques in the affected regions correlates extremely 
well with those regions involved in corticocortical association 
systems (113). It has been suggested on a purely anatomical basis 
that the disease process may progress along these putative EAA 
connecting pathways (99). Although these studies provide strong 
evidence that the characteristic pathology of Alzheimer's disease 
distributes in relation to EAA cortical association pathways, the 
mechanism by which plaques and neurofibrillary tangles organize 
along these pathways is unknown. EAA receptor-mediated mech- 
anisms may play a role in this distribution and contribute to the 
degeneration of neurons which are already compromised. How- 
ever, receptor distribution alone cannot explain the regional 
localization of neuron loss, plaques and neurofibrillary tangles, as 
discussed below. 
Dendritic Changes 
During the course of Alzheimer's disease, there is a loss of 
normal dendritic elements and a progressive simplification of the 
dendritic arbor of cortical neurons (71,80). Subtoxic doses of 
glutamate induce identical regression of dendrites in cultured 
hippocampus neurons (75,76). The affected dendrites are found 
primarily on pyramidal projection cells which normally receive 
extensive synaptic input from other cortical EAA neurons. A loss 
of the dendritic arbor would be expected to impair communication 
between regions of cortex. 
In some cases, in addition to the loss of normal dendrites and 
dendritic spines, there is a proliferation of abnormal, bizarre 
dendritic structures (56,107). In these instances, aberrant filopodia 
are often present (56,107). Similar filopodia-like structures are 
seen transiently after focal application of glutamate in cultured 
neurons [(129) and Mattson M.P., personal communication]. 
Thus, in cultured neurons, EAA can reproduce some of the 
dendritic changes seen in Alzheimer's disease. The relevance to 
the changes in Alzheimer's disease of this potential for EAA to 
modify dendritic structure is not yet known. 
EAA and the Pathogenesis of Alzheimer's Disease 
Do EAA play a role in the pathogenesis of Alzheimer's 
disease? The current evidence is tantalizing but only circumstan- 
tial. Similar to Alzheimer's disease, EAA can reduce neuronal 
RNA content, may induce the formation of paired helical fila- 
ments, and can cause regression of the pyramidal cell dendritic 
arbor. Furthermore, the distribution of pathology in Alzheimer's 
disease appears to be intimately related to EAA corticocortical 
association pathways. 
What role, if any do EAA receptors play in the pathogenesis of 
this disorder? The loss of EAA receptors in the cortex and 
hippocampus in Alzheimer's disease might be interpreted as being 
consistent with a loss of structures containing EAA receptors via 
an excitotoxic mechanism. Alternatively, the loss of EAA recep- 
tors could simply be due to shrinkage of the dendritic arbor of 
cortical and hippocampal pyramidal neurons, or could reflect 
neuronal loss, as suggested by Cotman and colleagues (42). 
NMDA receptor losses do appear to be related to the severity of 
pathology but this is not a simple relationship since the distribution 
of NMDA receptor losses and the regional pattern of pathological 
changes in Alzheimer's disease are poorly correlated, as discussed 
below. 
Because the distribution of pathology in Alzheimer's disease 
appears to occur in relation to EAA association pathways (37.99, 
113), and because postsynaptic NMDA receptors mediate excito- 
toxic events, it could be argued that the distribution of NMDA 
receptors should be a major determinant of the regional localiza- 
tion of pathological changes. Alternatively, the presence of 
NMDA receptors could be necessary but not sufficient to cause 
these changes; other factors such as density of EAA afferents, or 
intrinsic properties of the neurons such as their relative efficiency 
in sodium-calcium exchange, might then determine relative vul- 
nerability. 
Based on a comparison of NMDA receptors in normal brains 
and pathological changes in Alzheimer's disease, it does not 
appear that NMDA receptor localization is the major determinant 
of the distribution of pathology. In normal human hippocampal 
formation, NMDA receptor binding is highest in CA1, with less 
binding in the stratum moleculare of the dentate gyrus; CA3 and 
subiculum both have considerably lesser densities of binding than 
the CA1 region; entorhinal cortex appears to have even less 
binding than subiculum (42, 46, 72, 111). This rank order of 
NMDA receptor density in human hippocampus is similar to that 
seen in rat brain (45, 83, 85). In contrast, neuronal loss is most 
severe, and neurofibrillary tangles and senile plaques are most 
concentrated in entorhinal cortex, subiculum and CA1 region 
(54,55), while dentate gyrus and CA3 are relatively spared. Thus, 
more severe pathology can affect regions with fewer NMDA 
receptors, and areas rich in NMDA receptors may show little 
pathological involvement. The distribution of NMDA receptors in 
various regions of neocortex has not been studied in detail and the 
relationship between NMDA receptors and neocortical pathology 
is largely unknown. 
It is apparent from the studies to date that NMDA receptor 
distribution is not the major factor determining the regional pattern 
of pathological changes in Alzheimer's disease. It is also clear that 
NMDA receptor loss is not a simple reflection of cell loss because 
receptors are relatively spared in some regions where there is 
substantial cell loss (i.e., temporal cortex and subiculum) and are 
decreased in areas where there is little neuronal depletion 
(i.e., CA3). 
If excitotoxic mechanisms are still to be invoked in the 
pathogenesis of the degenerative changes of Alzheimer's disease, 
what can account for the distribution of these changes? Is it useful 
to consider the excitotoxic hypothesis of hypoxic/ischemic hippo- 
campal damage. Hypoxia/ischemia causes a large increase in 
extracellular glutamate levels by both increasing glutamate release 
(9) and impairing severely the high affinity uptake system which 
normally inactivates EAA (120). This results in elevated glutamate 
levels in the synaptic cleft and prolonged activation of EAA 
receptors. The pattern of neuronal damage in the hippocampus 
after hypoxic/ischemic insults is almost identical to that in Alzhei- 
mer's disease: CA1 neurons are severely damaged and CA3 and 
dentate gyms neurons are relatively unaffected (14). This pattern 
cannot be simply related to NMDA receptor distribution, yet 
NMDA receptor antagonists confer a profound protection from 
hypoxic/isehemic damage (114,115). This indicates that activation 
of NMDA receptors is involved in the pathogenesis of hypoxic/ 
ischemic damage, but NMDA receptor distribution alone does not 
determine the regional pattern of excitotoxic damage. 
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Recent work by Mattson and Kater (77) suggests that EAA 
receptors may play a necessary permissive role in excitotoxicity, 
but intrinsic properties of neurons from different regions may 
determine their relative vulnerability to excitotoxic damage. Neu- 
rons from subfields of the hippocampus were cultured separately 
and then exposed to toxic concentrations of glutamate. Pyramidal 
cells from the CAI region were selectively vulnerable, whereas 
pyramidal neurons from CA3 and granule cells from the dentate 
gyms were relatively resistant. This pattern of selective vulnera- 
bility is similar to that observed in hypoxia/ischemia and in 
Alzheimer's disease. Although these excitotoxic effects were 
mediated by NMDA receptors, it appears that there is some 
intrinsic property (or properties) of the neuron, related to its site of 
origin within the hippocampus, that determines its susceptibility to 
excitotoxins. Different neuronal populations may vary in their 
relative ability to handle increased intracellular calcium loads, in 
the efficiency of their intracellular calcium buffering system and in 
their capabilities for sodium-calcium exchange. Such differences 
may play a role in their selective vulnerability to neurotoxic 
damage. 
These findings may help explain the anatomical correlation 
between Alzheimer's disease pathology and cortical association 
pathways. EAA innervation and release via cortical association 
pathways, together with postsynaptic NMDA receptors, may 
provide a necessary but insufficient substrate for pathological 
excitotoxic damage. As yet undetermined intrinsic properties of 
regionally distinct groups of neurons may determine their relative 
vulnerability, and thus, the distribution of pathology. 
It is important to note that EAA could contribute to the 
distribution and severity of neuronal damage in Alzheimer's 
disease, even if an aberration of EAA systems were not the 
primary defect in this disorder. For example, when the energy 
stores of neurons are impaired, they are less able to maintain their 
normal membrane potential. This reduces the voltage-dependent 
magnesium blockade of the NMDA-associated ion channel and 
results in increased susceptibility to NMDA neurotoxicity (92). In 
this way, EAA may be a secondary cause of neuronal damage in 
Alzheimer's disease, and neurons which are compromised by 
some other pathological process may be rendered more vulnerable 
to EAA. 
THE RELATIONSHIP OF EAA CHANGES TO CLINICAL MANIFESTATIONS 
OF ALZHEIMER'S DISEASE 
Patients with Alzheimer's disease become progressively for- 
getful and develop profound abnormalities of cognition and 
orientation; signs of "cortical disconnection," such as apraxias, 
aphasias, and agnosias are also common. A defect in EAA 
neurotransmission may contribute to this clinical picture. EAA 
appear to be crucial in learning and memory (19,87). Activation of 
NMDA receptors is required for the development of long-term 
potentiation (a model of memory formation) in the CA 1 region and 
dentate gyrus of hippocampus in vitro. Competitive and noncom- 
petitive NMDA antagonists prevent the development of long-term 
potentiation, and perfusion of a competitive NMDA antagonist 
impairs spatial learning in vivo (19,87). The important role of 
EAA in learning and memory, together with evidence that cortical 
and basal forebrain cholinergic deficits alone are not sufficient to 
cause dementia (61), suggests that pre- and postsynaptic disruption 
of EAA transmission may contribute to the learning and memory 
deficits of Alzheimer's disease. The clinical signs of cortical 
disconnection may also result from disruption of glutamatergic 
pathways. Large pyramidal cortical neurons which give rise to 
association pathways are putatively glutamatergic (21,23) and 
pathological changes in these neurons are correlated with decline 
in mental test performance (89). The distribution of senile plaques 
and neurofibrillary tangles correlates closely with these EAA 
pathways. There is evidence, based on EAA levels, uptake and 
immunocytochemistry, that presynaptic EAA neurons are dam- 
aged in Alzheimer's disease. Furthermore, the loss of cortical and 
hippocampal EAA receptors and ion channels in Alzheimer's 
disease is likely to further impair communication between various 
regions of cortex. Thus, disruption of EAA neurotransmission 
could potentially play a very important role in the clinical signs 
and symptoms of Alzheimer's disease patients. 
THERAPEUTIC MODULATION OF EAA IN ALZHEIMER'S DISEASE 
In recent years, the principal target of therapy for Alzbeimer's 
disease has been the muscarinic cholinergic system. However, 
evidence suggests that the cholinergic system is not invariably 
affected in demented Alzheimer's disease patients. Further, severe 
deficits of cortical and basal forebrain cholinergic activity are not 
necessarily associated with dementia (61). Therapeutic trials with 
muscarinic agonists and acetylcholinesterase inhibitors have been 
largely unsuccessful (7). The one possible exception to this failure 
of cholinergic therapy has been a preliminary trial with tetrahydro- 
9-aminoacridine (THA) (135). THA is a potent acetylcholines- 
terase inhibitor with an ICso of 0.1-0.2 R~M (98). At concentra- 
tions above 1.0 ~M, THA also acts as a muscarinic (M1 and M2) 
antagonist (98). Thus, if THA were present in brain concentrations 
in the low micromolar range, the blockade of muscarinic receptors 
would be expected to offset the anticholinesterase effects of THA. 
At slightly higher concentrations, THA interacts with the NMDA 
ion channel/PCP receptor site (2). It has recently been found in 
mice that a single dose of THA which produces a therapeutic 
plasma level, results in a ten-fold concentration of THA in the 
brain, with peak THA concentrations of 2.4 p~M (66). Conceiv- 
ably, on a regular dosing schedule, steady-state concentrations of 
THA in brain could be even higher than after the single dose used 
in this study. At this reported concentration, THA could be 
expected to have significant cholinergic antagonist effects, and 
would also act at the NMDA ion channel. This raises the 
possibility that the effects of THA on the muscarinic system may 
be less important than previously thought, and the interaction with 
the PCP receptor may be clinically relevant. 
There is indirect clinical evidence that THA may be an 
antagonist of PCP receptors. It reverses magnesium chloride- 
induced coma (119) and decreases the duration of anesthesia 
produced by the dissociative anesthetics, phencyclidine and ket- 
amine (1). Furthermore, THA potentiates quinolinate's NMDA 
receptor-mediated toxicity (148), presumably by its interaction 
with the PCP site (2). In this way, THA may actually augment 
EAA neurotransmission at the NMDA receptor site. 
Because disruption of EAA neurotransmission could possibly 
produce some of the clinical manifestations of Alzheimer's dis- 
ease, treatment with EAA agonists might theoretically be of some 
benefit. It has even been suggested that "clinical trims examining 
the therapeutic efficacy of glutamate in this disorder are warrant- 
ed" (33). While augmentation of the EAA system in Alzheimer's 
disease may seem attractive, it is probably not feasible and is 
potentially quite dangerous. Under normal circumstances, the 
acidic amino acid transport system by which glutamate is translo- 
cated across the blood-brain barrier is saturated with ambient 
plasma concentrations of EAA (97). Furthermore, the concentra- 
tion of glutamate in brain is approximately 5-10 raM. Thus, it 
seems unlikely that manipulation of plasma concentrations of EAA 
would significantly alter brain levels of these compounds, unless 
extremely high doses were used (139). In Alzheimer's disease, 
there may be a disruption of the blood-brain barrier (146) and 
glutamate might enter the brain more freely. Because of a loss of 
neuronal glutamate uptake sites (108l, higher levels of glutamate 
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would more likely be toxic. In this regard, it is relevant that 
chronic administration of an excitotoxin with a lower potency than 
glutamate, in doses of 0 .7-2 .0  mmol/kg/day, causes extensive 
damage to cortical pyramidal cells in primates (133). 
If EAA-induced neurotoxicity plays either a primary or sec- 
ondary role in the pathogenesis of Alzheimer 's  disease, it might be 
expected that EAA antagonists would retard the progression of this 
disorder. The involvement of EAA in learning and memory, 
however, means that direct EAA antagonism would likely further 
impair Alzheimer 's  patients. 
Given our current understanding of EAA pharmacology, it is 
unlikely that EAA agonist or antagonist therapy will be of benefit. 
However, EAA pharmacology is complex and there are multiple 
sites at which potential therapeutic agents might be directed. For 
example, the glycine recognition site on the NMDA receptor 
complex must be occupied by an "agon i s t "  (glycine-like) com- 
pound in order for the NMDA receptor to be functional (62). 
Modulation of this site with agonist, antagonist or mixed agonist- 
antagonist drugs may produce clinically beneficial results with 
minimal side effects. In a similar fashion, drugs which modify 
PCP receptor function may be useful. In addition, it may be 
possible to exploit EAA agonists as "cognit ion enhancing"  drugs, 
by combining their use with agents that block specifically the 
postreceptor mechanisms responsible for toxicity. There may also 
be different agonist- and antagonist-preferring states of the NMDA 
receptor (84), selective modulation of which may be of clinical 
utility. 
SUMMARY 
Excitatory amino acids, particularly glutamate and aspartate, 
are the major excitatory neurotransmitters of the cerebral cortex 
and hippocampus. Pre- and postsynaptic defects in EAA neuro- 
transmission may account, in part, for the clinical manifestations 
of Alzheimer 's  disease. The excitotoxic properties of EAA might 
contribute to the pathogenesis of this disorder. Further study of 
EAA in Alzheimer 's  disease may lead to a better understanding of 
the cause of this devastating illness and might lead to new 
therapeutic strategies. 
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